Review Article
RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury

Sabien van Neerven¹,² and Jörg Mey¹,²

¹ Institute of Biology II, RWTH Aachen University, 52056 Aachen, Germany
² EURON Graduate School of Neuroscience, 6229 Maastricht, The Netherlands

Correspondence should be addressed to Jörg Mey, mey@bio2.rwth-aachen.de

Received 23 December 2006; Accepted 28 February 2007

Recommended by Bradley Taylor

The retinoic acid receptors (RAR) and peroxisome proliferator-activated receptors (PPAR) have been implicated in the regulation of inflammatory reactions. Both receptor families contain ligand-activated transcription factors which form heterodimers with retinoid X receptors (RXR). We review data that imply RAR/RXR and PPAR/RXR pathways in physiological reactions after spinal cord injury. Experiments show how RAR signaling may improve axonal regeneration and modulate reactions of glia cells. While anti-inflammatory properties of PPAR are well documented in the periphery, their possible roles in the central nervous system have only recently become evident. Due to its anti-inflammatory function this transcription factor family promises to be a useful target after spinal cord or brain lesions.

1. INTRODUCTION

During the last decade much progress has been made disentangling the physiological responses after central nervous system (CNS) injury. Yet, there is still no effective treatment available to prevent the devastating effects that result from major CNS lesions. Although neurite sprouting and axonal growth is observed after spinal cord injury (SCI), successful regeneration beyond the lesion-induced scar does not occur. In contrast, axonal regeneration with functional recovery is possible in the peripheral nervous system (PNS). The different outcomes of CNS and PNS lesions are largely due to differences in the cellular and molecular signals that neurons encounter in these environments. Three important problems after CNS injury are (1) development of a growth inhibitory glial scar, (2) secondary neuronal and glial degeneration as a delayed consequence of the lesion, and (3) the failure of axonal regeneration in white matter tracts. Responding to these problems, most attention has been directed either to overcome the inhibitory barrier of the glial scar or to promote the growth of axon collaterals and thus compensate for permanently severed connections [1–3]. A subsidiary approach is to modify inflammatory reactions in order to limit the secondary degeneration. Synthetic corticosteroids, e.g., methylprednisolone, are the only pharmacological tools currently in clinical use [4]. In this review, we will discuss two nuclear receptor families that have recently been discovered as possible therapeutic targets for the treatment of SCI and brain damage. Retinoic acid receptor (RAR) signaling may improve axonal regeneration, influence glial differentiation, and modulate inflammatory reactions [5]. Peroxisome proliferator-activated receptors (PPAR) have a major function in anti-inflammatory processes [6]. Both receptor classes, RAR and PPAR, heterodimerize with retinoid X receptors (RXR) to form active transcription factors.

2. ENDOGENOUS RAR/RXR AND PPAR/RXR ACTIVITY IN THE INJURED NERVOUS SYSTEM

2.1. RAR/RXR signal transduction

The RAR/RXR transcription factor complex is activated by ligand binding, its natural ligand being all-trans retinoic acid (all-trans RA). Retinooids are obtained from the diet in the form of vitamin A (retinol and retinal), retinyl esters, or β-carotene. Following cellular uptake of all-trans retinol from the plasma, the intracellular synthesis of retinoic acid occurs in two steps. (1) Retinol is oxidized to retinal, predominantly involving the alcohol dehydrogenases ADH-1, -3, and -4. (2) The critical step is the subsequent oxidation of retinal to retinoic acid by retinaldehyde dehydrogenases (RALDH) [7]. Retinoic acid is released in a paracrine or autocrine fashion. The fact that RA activates nuclear transcription factors
was discovered in 1987 [8, 9]. Retinoid receptors belong to the same superfamily as PPAR, thyroid hormone receptors (TR), and steroid receptors. They can be grouped into two families, the RARs and the RXRs, each consisting of three isoforms encoded by separate genes: RAR α, RAR β, RAR γ (also: NR1B1-3) and RXRA, RXRB, RXRY (NR2B1-3). All-trans RA and 9-cis RA bind to the RAR family, whereas only 9-cis RA is a high-affinity ligand for the RXR [7, 10]. The active transcription factor complex consists of an RAR/RXR heterodimer, ligand, and coactivators. It interacts with retinoic acid response elements (RARE) in the promoters of target genes. About 500 genes have been suggested to be regulated by RAR/RXR signaling, however a much lower number was experimentally shown to be activated via the classical RARE driven pathway. Proven target genes include enzymes, transcription factors, cytokines, and cytokine receptors [5, 11]. In addition, many cases of gene suppression and nongenomic modes of action of RA and its receptors have been described [7].

2.2. RAR/RXR signaling after spinal cord injury

The discovery that enzyme activity of a retinaldehyde dehydrogenase increased after spinal cord contusion injury was the first direct evidence that retinoids play a role in the physiological responses to SCI. Contusion injury caused a significant increase in RALDH2 enzyme activity, which peaked 8–14 days following the lesion [12]. While in the uninjured rat spinal cord RALDH2 is only present in the meninges, oligodendrocytes and in pericytes, around the lesion site, its immunoreactivity also appeared in a population of NG2-positive glia cells [13] (Figure 1(a)). NG2 is a chondroitin sulfate proteoglycan, expressed in cells that have been described as oligodendrocyte precursor cells, satellite cells or oligodendrocytes. These cells respond to injury with increased production of NG2 and a subpopulation of them, close to the lesion site, appears to be involved in the local production of RA. Alternatively or additionally, RA-synthesizing cells migrate from the adjacent arachnoid membrane and from blood vessels toward the site of injury [13]. While only minor changes in the quantitative expression of retinoid receptors were observed after SCI, their cellular distribution changed remarkably (Figures 1(b), 1(c)). In the uninjured tissue, retinoid receptors were found in the cytosol of motoneurons and glia, but close to the injury site macrophages and surviving neurons displayed a nuclear localization of RARα, RXRa, and RXRB [14]. In the context of locally rising RA synthesis, the observation that retinoid receptors translocate into the cell nuclei indicates that neurons, glia, and macrophages are targets of RA signaling after SCI. This interpretation is consistent with data on spinal cord development, where RA has been shown to be a regulator of cell differentiation [15–18].

2.3. RAR/RXR signaling after peripheral nerve injury

RA signaling is implicated in the differentiation of neurons whose axons grow in the PNS, [19–22] and again in neurite regeneration [23, 24]. Several mediators of the RA signaling pathway have been shown to be induced after peripheral nerve injury in the rat. Experimental lesion of the sciatic nerve induced expression of the cellular retinol binding protein-I (CRBP-I) [25], which is implicated in retinoid metabolism [26]. Similarly, transcript and protein concentrations of the cellular retinoic acid binding protein-II (CRABP-II) increased strongly [25]. CRABP-II is probably involved in the intracellular transport of RA to the cell nucleus [27]. As after SCI, the RA-synthesizing enzyme RALDH2 was present in the injured nerve. After sciatic nerve injury in transgenic reporter mice, local activation of RARE was detectable in the regenerating nerve, indicating that RA-dependent gene expression is induced during peripheral nerve regeneration [25]. The expression of retinoid receptors also changed significantly. Following sciatic nerve crush, mRNA of all RARs and of RXRs was increased, and at 4, 7, and 14 days after the injury protein levels of RARα, RARβ, and RXRa were augmented [28]. To study Wallerian degeneration in the absence of axonal regeneration, the distal nerve segment can be cut off and sutured to the peroneus muscle. Under these conditions RARα and RARβ were upregulated in the degenerating nerve.

Cell culture experiments indicated that RARβ is required for RA-induced axonal regeneration [24]. Consequently, experiments with RARβ-deficient mice corroborated this interpretation because there were significantly less GAP43-positive, regenerating axons after sciatic nerve crush in the knockout animals [29]. Since RALDH2 [23] and RARβ [30] are induced by NGF, RA appears to act downstream of this neurotrophin. RA/RARβ signaling seemed to be necessary for the neurotrophic activity of NGF [23]. In addition, neurotrophin-independent RA/RARβ activity contributes to axon outgrowth [29]. Double labeling with cell type specific markers in the sciatic nerve demonstrated expression of retinoid receptors mostly in macrophages and Schwann cells. In cultured primary Schwann cells, RA downregulated CNTF [31] and raised expression of ErbB3, a neuregulin receptor that is necessary for normal myelination. Finally, RXRa labeling was shown to colocalize with some regenerating axons, indicative of a direct role for RXRa in nerve regeneration [28].

2.4. PPAR/RXR signal transduction

Peroxisome proliferator-activated receptors belong to the same superfamily as the RAR. The first PPAR was discovered, cloned, and sequenced in 1990, and it was named after its property to be activated by drugs that cause proliferation of peroxisomes in hepatocytes [32]. Until now, three different isoforms of PPAR, encoded by separate genes, have been identified: PPARα (NR1C1), PPARβ/δ (NUC1, NR1C2), and PPARγ (NR1C3). The different isoforms have similar structural features, however each isoform exhibits its own specific tissue expression pattern and distinct physiological functions depending on ligand activation [33, 34]. PPAR also heterodimerize with RXR, then bind as a complex to their response elements (PPRE). These consist of
two repeats of the consensus sequence AGGTCA separated by one or two nucleotides (direct repeats DR-1 and DR-2) [35]. Natural ligands of PPAR are fatty acids, prostaglandins, and oxidized fatty acid derivatives. They are also activated by synthetic ligands like the lipid-lowering fibrates and the anti-diabetic glitazones [36]. PPAR, which have been implicated in lipid metabolism, cellular proliferation and inflammatory responses, are widely expressed, for example, in colon, spleen, retina, the cardiovascular system, liver, skeletal muscles, and in adipose tissue. Their expression by monocytes, dendritic cells, endothelial cells, megakaryocytes, and lymphocytes may be related to immune functions [34, 36]. PPARγ can also influence gene expression independently of PPRE. The activity of a number of transcription factors, for example, NFκB, AP-1, and STAT-1, are inhibited by PPARγ via direct interaction or by competition for limiting supplies of coactivators [6].

### 2.5. PPAR/RXR signaling after spinal cord injury

PPAR are expressed in the developing and adult CNS. PPARα and PPARβ/δ, but not PPARγ were found in cervical, thoracic, and lumbar segments of the adult spinal cord, in the thalamus and cerebral cortex [37] (Figure 2). Immunohistochemical staining showed that PPARβ/δ is the main isoform present in neuronal cell bodies of the spinal cord gray matter. Both receptors, PPARα and PPARβ/δ, were concentrated in cell nuclei. In the white matter PPARα appeared particularly strong in PPARβ/δ-negative astrocytes, whereas oligodendrocytes expressed only PPARβ/δ [38]. PPARβ/δ is a factor in neuronal differentiation, and functions of this re-
ceptor in various aspects of neural physiology have been sug-
gested [38, 39]. While in two studies PPARy could not be
detected in brain and spinal cord [37, 38], this receptor is ex-
pressed in microglial primary cultures [40] and may be up-
regulated after injury. In a different report, all PPAR and RXR
were found immunohistochemically throughout the adult
rat CNS [41].

Endogenous PPAR ligands may play a role in modulat-
ing the inflammatory response after SCI, possibly preventing
the expansion of the initial damage. Genovese and cowork-
ers [42] examined the e
fects of endogenous PPARa ligands
in an experimental model of spinal cord trauma. SCI was in-
duced in wild-type and in PPARa-deficient (−/−) mice. The
injury resulted in severe trauma characterized by edema, loss
of myelin, neutrophil infiltration, apoptosis, and increased
production of TNFa. Compared to wild-type animals, all
these parameters were augmented in PPARa−/− mice. The
absence of PPARa also interfered with recovery of limb func-
tion [42]. Studies using animal models of chronic pain indi-
cate that PPARa is involved in the neural processing of pain
[43, 44].

3. REGULATION OF INFLAMMATORY
   PROCESSES BY RAR/RXR SIGNALING
   IN THE SPINAL CORD

Although the inflammatory response limits the effects of a
pathogenic insult, it is also responsible for most of the sec-
ondary damage incurred after spinal cord injury. The regula-
tion of these events is therefore of primary therapeutic con-
cern. Both pathways, RAR/RXR and PPAR/RXR signaling are
implicated.

3.1. Inflammatory reactions in the spinal cord

The physiological events following spinal cord injury can be
differentiated into an acute phase (the first 24hrs), fol-
lowed by a subacute phase (24–72hrs), and a late phase (3–90
days). Events after this time are considered chronic. CNS in-
jury directly leads to release of inflammatory signals result-
ing in the production of vasoactive mediators and chemo-
tactic factors. Primary damage consists mainly of severed
axons, neuronal and oligodendrocyte cell death. Expansion
of the initial damage is then caused by a disruption of the
blood supply and an extended inflammatory reaction. De-
pending on the type of injury, the blood-brain barrier is dis-
rupted. This event determines the extent to which blood-
derived cells participate in the inflammatory process [45, 46].
When the blood-brain barrier breaks down, the release of
cytokines and chemokines leads to a massive recruitment of
inflammatory cells from the periphery, including hematoge-
nous neutrophils and perivascular/meningeal macrophages.
These cells contribute to tissue damage by the production of
proteolytic enzymes and reactive oxygen species. Microglia
and macrophages phagocytose dead or injured neurons and
glia, and are responsible for the clearance of cellular debris
[45].

Microglia, perivascular macrophages, and activated as-
trocytes are the most important local sources of cytokines.
Astrocytes are further involved in the formation of a glial
scar, thereby insulating the healthy tissue from uncontrol-
lable processes in the damaged area. Acute inflammation can
develop into a chronic process when feedback mechanisms
fail to inhibit amplification of the inflammatory response.
Chronic inflammation leads to a continuous influx of neu-
trophils, macrophages, lymphocytes, and eosinophils from
the circulation, causing more tissue destruction and scarring.

3.2. RAR/RXR signaling is involved
   in inflammation

Before the molecular mechanisms of the retinoid signal-
ing pathway were understood, anti-inflammatory proper-
ties of RA had already been described. In 1983, a study
showed that oral administration of retinoids affected der-
al inflammatory cells and reduced elevated skin tempera-
ture [47]. Retinoic acid has beneficial effects in diseases with
an inflammatory-based pathology including asthma, arthri-
tis, and atherosclerosis [48, 49]. A number of cell culture
studies support the hypothesis that RA reduces inflammatory
activation of monocytes, macrophages, myeloma cells, and
polymorphonuclear cells (neutrophil granulocytes). Signals
that were found to be downregulated by retinoids include
IL-1α, IL-1β, IL-6, TNFa, IL-8, prostaglandin E2, pro-
duction of reactive oxygen species, and release of lysosomal en-
zymes. A table with these effects and references is presented
in [5]. In contrast to a majority of findings that indicate an
anti-inflammatory role of RAR/RXR signaling, it was also re-
ported that 9-cis RA induced secretion of MCP-1 and thereby
stimulated monocyte migration [50]. In combination with
T-cell stimulating agents, all-trans RA, 9-cis RA, and an RAR
agonist, TTNPB, indirectly increased proliferation of human
T lymphocytes and IL-2 secretion [51].

One of the major transcription factors responsible for the
regulation of inflammatory cytokines is NFkB. It was
shown that RXR inhibits NFkB-dependent gene expression
(IL-12) [52]. In the experiments, interference of RXR with
dNA binding of NFkB required the presence of the RXX
and 9-cis RA. The negative RXX/NFkB interaction appears
to be mutual because increasing levels of transfection with
NFkB subunits also abrogated expression of a retinoid re-
porter construct [52].

3.3. The role of RAR/RXR in inflammatory reactions
   after CNS injury

Although retinoic acid has so far not been used to mod-
ify inflammatory reactions in the CNS in vivo, cell culture
experiments demonstrate anti-inflammatory effects on mi-
croglia and astrocytes [5]. Primary cultures of microglia and
astrocytes are most frequently prepared from cerebral cor-
tex of perinatal rats and mice. One can expose these cultures
to LPS to simulate a bacterial infection, or treat them with
β-amyloid peptide (Aβ) to mimic the immunogenic stim-
ulus of Alzheimer’s disease. In this kind of experiment, RA
 treatment suppressed the induction of TNFa and iNOS. Ef-
fects correlated with enhanced expression of RARβ, TGFβ,
and inhibition of NFκB nuclear translocation [53]. Xu and Drew demonstrated that 9-cis RA suppressed LPS-induced production of NO as well as of proinflammatory cytokines TNFα, IL-1β, and IL-12p40 in primary mouse microglia, while IL-6 secretion and MCP-1 production were not significantly affected (Figure 3) [54]. In astrocytes from rat brain and in C6 astroglia cells, 9-cis RA and all-trans RA inhibited IFNγ-induced inflammatory responses [55].

Matrix metalloproteinases (MMP) are involved in the breakdown of the extracellular matrix and other proteins. These proteases are products of leukocytes and endothelial cells and are released in response to various cytokines and growth factors. Increased proteolytic activity of MMP can lead to disruption of the blood-brain barrier and escalate the inflammatory response [56, 57]. Retinoic acid has negative effects on secretion and expression of these enzymes. It reduced mRNA, protein synthesis, and secretion of MMP-9 (gelatinase B) in lymphocytes from patients with chronic B-lymphocytic leukemia and in human monocytes [58]. Other metalloproteinases including MMP-1 and MMP-13 appeared to be influenced by RA as well [59].
4. REGULATION OF INFLAMMATORY PROCESSES BY PPAR/RXR SIGNALING IN THE SPINAL CORD

4.1. PPAR/RXR signaling counteracts inflammatory processes

For the PPAR family, anti-inflammatory effects are well documented. One mechanism involves direct interaction of PPAR with proinflammatory transcription factors, most importantly NFκB and AP-1, and the subsequent reduction of gene transcription. This has been observed in vitro in human vascular endothelial cells [60], human aorta smooth muscle cells [61], in C2C12 skeletal muscle cells (in a model for insulin resistance in type 2 diabetes) [62], and in fibroblasts from rheumatoid arthritis patients [63]. PPAR knock-out studies supplement and confirm these results. One of the first reports indicating that PPARγ is involved in attenuating inflammation demonstrated that the eicosanoid LTB4 binds and activates PPARγ. Subsequently, PPARγ-deficient mice were shown to have a prolonged inflammatory response when challenged with LTB4 or arachidonic acid [64].

An interaction of PPARγ with NFκB is indicated by studies of inflammatory cytokine production in aging. In aged mice, NFκB becomes constitutively active in many tissues due to oxidative stress, which eventually leads to the production of cytokines. Administration of PPARγ activators was found to restore the cellular redox balance, to suppress the constitutive activation of NFκB and to eliminate the spontaneous production of IL-6 and IL-12 [65, 66]. Other examples where PPARγ−/− mice suffer from more severe inflammatory reactions are carrageenan-induced hypersensitivity [67], airway inflammation [68], and experimental colitis [69]. On the molecular level, these investigations demonstrated Fas-ligand, IL-1β, TNFα, keratinocyte-derived chemokine, MIP-2, MCP-1, ICAM-1, and enzyme activities of MMP-9, myeloperoxidase, and iNOS to be influenced by PPARγ signaling [67, 69, 70].

PPARγ-deficient mice die in utero, but heterozygotic PPARγ+/− mice with 50% expression of the receptor survive and can be studied. In an investigation of PPARγ functions after intestinal and gastric ischemia/reperfusion injury, PPARγ+/− mice displayed more severe lesions of the gastric intestinal mucosa. Treatment with the PPARγ ligand BRL-49653 limited the damage of intestinal injury and resulted in downregulation of cell adhesion molecules and proinflammatory cytokines in the intestine and stomach [71, 72]. As mentioned before, NFκB and inflammatory mediators are raised during the aging process. While this is accompanied by reduced PPARγ levels, the PPARγ ligand 2,4-TZD was shown to reduce age-related oxidative stress, the translocation of NFκB p65 subunit to the nucleus and NFκB-regulated transcription of iNOS, COX-2, IL-1β, IL-6, and the cell-adhesion molecule VCAM-1 [73]. Another PPARγ agonist, rosiglitazone, relieved renal injury in a nephrotoxicity model, also acting via inhibition of NFκB [74]. It seems therefore that both receptors PPARα and PPARγ play a general role in modulating the inflammatory response in a wide variety of tissues.

4.2. Effect of PPAR activation on macrophages, microglia, and astrocytes

Given that PPAR agonists influence peripheral macrophages [75], it was to be expected that they act on brain macrophages after disruption of the blood-brain barrier. PPARα is already present in undifferentiated monocytes, while PPARγ expression is induced during differentiation [76, 77] and upregulated in the course of macrophage activation [78–82]. A number of cell culture studies with macrophages and microglia demonstrate that agonists of PPARα and PPARγ elicit the same anti-inflammatory effects that we have discussed above. When cells were activated with bacterial antigens or Aβ, the PPAR ligands prevented or reduced the inflammatory response. This effect was observed on the following levels: (1) activity of transcription factors NFκB, AP-1, and STAT-1, (2) secretion of proinflammatory cytokines and chemokines, (3) enzyme activities of COX-2, iNOS, and MMP-9, and (4) the formation of reactive oxygen radicals. A synopsis of these results is presented in Table 1.

Such effects were observed with natural ligands, for example, prostaglandins, with artificial PPAR activators, for example, antidiabetic thiazolidinones, and with nonsteroid anti-inflammatory drugs [83]. A very efficient endogenous agonist of PPARγ is the prostaglandin 15d-PGJ2 [70]. However, this drug also interferes with the transcriptional activity of NFκB independently of PPARγ activation because overexpression of PPARγ or an antagonist of PPARγ did not alter the 15d-PGJ2 effect on LPS/IFNγ-dependent inflammatory reaction. It was concluded that 15d-PGJ2 inhibits the inflammatory response by directly regulating the NFκB and PI3K-Akt pathways [79, 84].

With respect to microglia effects on nerve cells, PPAR activation with synthetic ligands can be neuroprotective. When cortical neurons were exposed to the cell-free supernatant from activated microglia, neurons survived better when microglia had also been incubated with PPARγ agonists [85]. Some experiments in vivo also support this concept. Oral administration of pioglitazone or the nonsteroidal anti-inflammatory drug ibuprofen, which is also a ligand for PPARγ, reduced the number of activated microglia and reactive astrocytes in the hippocampus and cerebral cortex. This was observed in 10-month-old APPV717I mice, an inflammation model for Alzheimer’s disease [83]. Pioglitazone protected mice also from MPTP-induced dopaminergic neuronal cell loss and mitigated inflammatory response by microglia in an animal model of Parkinson’s disease [86].

As mentioned before, astrocytes participate in the secretion of cytokines and form a glial scar around the damaged tissue. Since the production of microglia primary cultures also involves isolation of astrocytes, it was a straightforward approach to test PPAR agonists on this type of glia as well (Figure 3) [87–89]. Results, which were generally in line with the anti-inflammatory effects on microglia, are also included in Table 1.
Figure 3: Anti-inflammatory effects of PPAR and RAR agonists in astrocytes. Astrocyte primary cultures from cortices of newborn mice were treated with 9-cis RA (RA) and/or the PPARα agonist fenofibrate (F) for 1 hour and then stimulated with 2μg/mL LPS for 24 hours. (a) Nitrite production as an indicator of NOS activity was reduced by 1μM RA or 100μM F, and completely suppressed with RA plus F. Pretreatment of RA and/or F also decreased the release of (b) the chemokine MCP-1 (RA: 2μM, F: 200μM), and cytokines (c) IL-1β (RA: 1μM, F: 100μM), (d) IL-6 (RA: 2μM, F: 50μM), and (e) TNFα (RA: 1μM, F: 100μM) in response to LPS. Cytokine production was measured with ELISA. Experiments with microglia cultures revealed similar effects, except for MCP-1, whose production was stimulated by 9-cis RA in microglia. Error bars indicate SEM, asterisks indicate significant differences compared to the LPS condition (sources: [54, 78]).

5. APPLICATION OF RETINOIDS AND PPAR LIGANDS AFTER SPINAL CORD AND PERIPHERAL NERVE INJURY

Retinoic acid is a well-characterized morphogenetic factor in embryonic development. Stem cells and several cell lines can be induced with RA to differentiate to a neuronal phenotype. A number of experiments with developing sympathetic neurons and with sensory neurons from dorsal root ganglia revealed that RA has neurotrophic effects or induces neurite growth. The question arises whether these properties can be exploited to support axonal regeneration [5, 90].
5.1. Retinoic acid-induced axonal growth in vitro and in vivo

While the most convincing demonstration that RA can act as an axon-guiding chemoattractant was recently published using the snail Lymnaea stagnalis [91], a number of earlier studies indicated that retinoids may fulfill similar functions in vertebrates. Neurites extending from chick neural tube cells responded to a gradient of RA [92]. Positive effects on axon outgrowth were also reported using explants from murine embryonic spinal cord [93], embryonic cerebellum [94], and amphibian spinal cord [95]. In a chick retinal explant assay, RA enhanced neurite outgrowth under the condition that the neurotrophin BDNF was subsequently added in vitro [96]. RA supported survival and morphological differentiation of cultured rat spinal cord neurons and increased neurite density. In this context, astrocytes were implicated as regulators of local RA concentration [16, 17].

Corcoran, Maden, and coworkers suggested that the loss of regeneration in the adult mammalian CNS is related to developmental changes in retinoid signaling. They observed that the RARβ2 receptor, which is present when neurite outgrowth occurs from embryonic spinal cord explants, was not detectable in the adult spinal cord [97]. A supporting result was that specifically RARβ mediated the induction of neurite outgrowth from subpopulations of sensory neurons [24]. In addition to the inhibitory glial environment [1], intrinsic changes in CNS neurons have been assumed to be responsible for the loss of regenerative ability during CNS development [98]. The declining expression of RARβ2 may be one of those changes. To test this hypothesis, the RARβ2 gene was transfected into spinal cord explants with a lentiviral vector. This treatment allowed the outgrowth of many neurites, implicating the involvement of RARβ2 in axonal regeneration [97]. Consequently, to demonstrate that a renewed expression of the appropriate receptor mechanism might induce axonal regeneration into the spinal cord in vivo, Wong and others [99] transfected RARβ2 in adult rats. They then analyzed regeneration of sensory axons into the spinal cord and performed behavioral experiments. Following complete dorsal root transections by means of a crush injury, axons regrown across the dorsal root entry zone into the CNS. Both myelinated and nonmyelinated fibers were found to have grown in the spinal cord where they projected into the gray matter, formed functional connections and improved sensormotor recovery of the animals [99]. In another study, artificially induced RARβ2 expression also supported regeneration of descending corticospinal tract fibers after midcervical spinal cord injury (Figure 4). Again, the induced regeneration of fibers was accompanied by improved sensory and locomotor behavior [100]. These data suggest not only that RARβ is involved in activating a physiological program of regeneration but also that retinoic acid signaling may be used as a therapeutic tool in spinal cord injury.

5.2. Manipulation of RAR/RXR signaling in the peripheral nervous system

As mentioned above, it has been known for some time that retinoids act as neurotrophic factors for sympathetic and sensory neurons of the peripheral nervous system [20–24]. However, very few studies have addressed the role of RA in peripheral nerve regeneration in vivo. Taha and coworkers tested whether local RA injections improved morphological and functional regeneration of tibial nerves undergoing anastomosis. They showed that animals injected locally with RA exhibited increased axonal density when compared to vehicle-treated animals [101]. Several cell culture experiments suggested that RA effects may involve an up-regulation of neurotrophin receptors, and molecular studies indicate mutually synergistic influences of the RA- and neurotrophin-signaling pathways. Nerve growth factor induced the RA-synthesizing enzyme RALDH in dorsal root ganglia [23] and activated the RARβ promoter [30]. RA, on the other hand, caused expression of various neurotrophin receptors (see [5, 90] for review). That synergistic interactions between RA and neurotrophins take place in vivo was revealed in a study using a mouse model for diabetes [102]. Treatment of the animals with all-trans RA via subcutaneous injection in a dose of 20mg/kg was able to prevent the NGF depletion normally seen in diabetic mice. Microscopic analysis subsequently showed that diabetes-associated loss of Schwann cells, of myelinated, and of nonmyelinated axons was strongly reduced by RA. This beneficial effect was also measurable in behavioral tests of sensory-motor functions [102].

5.3. Retinoids and PPAR ligands in pain signaling

In a different line of research about spinal cord sensitization, some contrasting results were obtained recently. To investigate whether retinoids might be involved in the processing of nociceptive information, especially in situations of hyperalgesia due to inflammation, rats were given 10–15mg/kg all-trans RA orally for 4 days. Electrophysiological recordings revealed that treated animals had decreased thresholds to mechanical and electrical stimulation of the paws and increased cutaneous receptive fields. This increased responsiveness caused by RA was similar to hyperalgesia induced by intraplantar administration of carrageenan (which leads to local inflammation) [103]. On the molecular level, RA induced changes of gene expression in the spinal cord, for instance, an increase of COX-2 and IL-1. Inhibition of these pathways with IL-1 receptor antagonist and the COX-inhibitor dextemetoprofen reduced responses to mechanical or thermal stimulation when those had been sensitized with RA [104]. In these studies, it was concluded that all-trans RA induced changes in the spinal cord that are similar to inflammation. At this point, it is difficult to reconcile this conclusion with the anti-inflammatory properties when RA was combined with stimuli of bacterial infection or Aβ deposition.

In contrast to RA, administration of the PPARα agonists GW7647, Wy14643, perfluorooctanoic acid, and PEA reduced nociceptive behaviors in various animal models of hyperalgesia, implicating a mitigating role of PPAR in the regulation of pain signaling [43, 44]. GW7647 and PEA also prevented firing of spinal cord nociceptive neurons in rats after peripheral exposure to formalin [44].
5.4. Use of PPAR ligands as anti-inflammatory treatment after spinal cord injury

The knowledge about anti-inflammatory properties of PPAR ligands obtained in cell cultures soon prompted animal experiments. In these, PPARα ligands were indeed shown to exert neuroprotective effects after traumatic brain injury [105]. Recently, it was discovered that synthetic PPARγ ligands rosiglitazone and pioglitazone are also neuroprotective by reducing the inflammation in the spinal cord. Treatment of rats directly after SCI resulted in a decreased lesion site, better survival of motor neurons, sparing of myelin, reduced
Table 1: Anti-inflammatory effects of PPARα and PPARγ agonists on the molecular level.

<table>
<thead>
<tr>
<th>Experimental system</th>
<th>Nuclear receptor</th>
<th>Regulated signals</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokine- and LPS-stimulated microglia</td>
<td>PPARα, RXR</td>
<td>NO synthesis, IL-1β, IL-6, IL-12p40, TNFα, MCP-1</td>
<td>[78]</td>
</tr>
<tr>
<td>Activated macrophages</td>
<td>PPARα, γ</td>
<td>iNOS, heme oxygenase (COX-2, HSP70 not affected)</td>
<td>[70]</td>
</tr>
<tr>
<td>Activated macrophages</td>
<td>PPARγ</td>
<td>iNOS, MMP-9, scavenger receptor A</td>
<td>[80]</td>
</tr>
<tr>
<td>Activated human monocytes</td>
<td>PPARγ</td>
<td>IL-1β, IL-6, TNFα</td>
<td>[81]</td>
</tr>
<tr>
<td>Activated macrophages</td>
<td>PPARγ</td>
<td>Reactive oxygen species</td>
<td>[77]</td>
</tr>
<tr>
<td>LPS-stimulated microglia</td>
<td>PPARγ</td>
<td>IL-1β, IL-6, TNFα, MCP-1, iNOS</td>
<td>[87]</td>
</tr>
<tr>
<td>LPS-stimulated microglia</td>
<td>PPARγ</td>
<td>IL-6, TNFα, iNOS, COX-2</td>
<td>[85]</td>
</tr>
<tr>
<td>Aβ-stimulated microglia</td>
<td>PPARγ</td>
<td>IL-1β, TNFα, COX-2</td>
<td>[82]</td>
</tr>
<tr>
<td>LPS-stimulated astrocytes</td>
<td>PPARα, RXR</td>
<td>IL-1β, IL-6, TNFα, iNOS, MCP-1</td>
<td>[88]</td>
</tr>
<tr>
<td>LPS-stimulated astrocytes</td>
<td>PPARγ</td>
<td>IL-6, TNFα, iNOS, COX-2</td>
<td>[85]</td>
</tr>
<tr>
<td>LPS-stimulated astrocytes</td>
<td>PPARγ</td>
<td>IL-1β, IL-6, TNFα, MCP-1, iNOS</td>
<td>[87]</td>
</tr>
<tr>
<td>Cerebellar injection of IFNγ, LPS</td>
<td>PPARγ</td>
<td>iNOS, cell death</td>
<td>[89]</td>
</tr>
<tr>
<td>MPTP-treated mice</td>
<td>PPARγ</td>
<td>iNOS, IkB, cell death</td>
<td>[86]</td>
</tr>
<tr>
<td>APPV717I transgenic mice</td>
<td>PPARγ</td>
<td>iNOS, COX-2, β-amyloid</td>
<td>[83]</td>
</tr>
<tr>
<td>Rat spinal cord injury</td>
<td>PPARγ</td>
<td>IRF-1, IL-1β, IL-6, MCP-1, ICAM, Egr-1</td>
<td>[106]</td>
</tr>
<tr>
<td>Rat model for stroke</td>
<td>PPARγ</td>
<td>IL-1β, iNOS, COX-2</td>
<td>[107]</td>
</tr>
</tbody>
</table>

These features were accompanied by enhanced functional motor recovery and reduced hyperalgesia [106]. Investigation of gene expression revealed that pioglitazone lowered levels of transcription factors IRF-1, NFκB, transmembrane proteins Egr-1, ICAM, and cytokine/chemokines IL-1β, IL-6, MCP-1, but increased expression of neuroprotective genes and antioxidant enzymes. In a rat model for stroke (middle cerebral artery occlusion), PPARγ ligands were able to improve neurological outcome, decreased infarct size, and reduced inflammation. Fewer microglia/macrophages appeared to be present, and transcript and protein levels of IL-1, COX-2, and iNOS were also lower [107].

6. CONCLUSION

The studies discussed here demonstrate that RAR/RXR and PPAR/RXR signaling may be therapeutic targets after spinal cord injury. The main potential of PPAR ligands derives from their anti-inflammatory capacity, which has been corroborated in rodent models of inflammation involving various peripheral organs. After spinal cord injury, inflammatory reactions account for a large proportion of the secondary damage to neurons and oligodendrocytes. In this context, first experiments show that PPAR ligands are neuroprotective. Since PPAR activators are already in use to treat diabetes, clinical studies after stroke or other kinds of CNS damage are to be expected. While retinoids also have anti-inflammatory properties, they exert more direct effects on the nerve tissue. In several populations of neurons, axonal regeneration can be induced or supported by the activation of RAR/RXR signaling. Since systemic application of retinoic acid influences neural physiology within the CNS, therapeutic possibilities arise here as well. As in the case of cancer treatment, an important consideration is the expression of retinoid receptors. After spinal cord injury the induction of RARβ appears to be a requirement. In addition to the classical transcriptional effects, retinoids and PPAR ligands can act via receptor-independent mechanisms. This, however, is a largely uncharted territory where therapeutic benefits remain to be discovered.

ABBREVIATIONS

Aβ: Beta amyloid peptide
ADH: Alcohol dehydrogenase
AP: Activating protein
BDA: Biotinylated dextran amine
BDNF: Brain-derived neurotrophic factor
CNS: Central nervous system
CNTF: Ciliary neurotrophic factor
COX: Cyclooxygenase
CRABP: Cellular retinoic acid binding protein
CRBP: Cellular retinol binding protein
dpo: dies post operationem
EGF: Epidermal growth factor
Egr: EGF receptor
ErbB: Tyrosine kinase related to the EGF receptor
GAP43: Growth associated protein 43
ICAM: Intercellular cell adhesion molecule
IFN: Interferon, IL–interleukin
iNOS: Inducible NO synthase
IRF: Interferon regulatory factor
LPS: Lipopolysaccharide
LTB₄: Leukotriene B4
MCP: Macrophage chemoattractant protein
MIP: Macrophage inflammatory protein
MMP: Matrix metalloproteinase
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NFkB: Nuclear factor κB
NGF: Nerve growth factor
NR: Nuclear receptor
PEA: Palmitoyl ethanolamide
15d-PGJ2: 15-deoxy-delta prostaglandin J2
PI3-K: Phosphoinositide 3-kinase
PNS: Peripheral nervous system
PPAR: Peroxisome proliferator-activated receptor
PPRE: PPAR response element
RA: Retinoic acid
RALDH: Retinaldehyde dehydrogenase
RAR: Retinoic acid receptor
RARE: Retinoic acid response element
RXR: Retinoid X receptor
SCI: Spinal cord injury
STAT: Signal transducer and activator of transcription
TGF: Transforming growth factor
TNF: Tumor necrosis factor
TR: Thyroid hormone receptor
TTNPB: 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic acid
2,4-TZD: 2,4-thiazolidinedione
VCAM: Vascular cell adhesion molecule

ACKNOWLEDGMENTS

S. van Neerven is supported by a Marie Curie Fellowship of the EURON Graduate School of Neuroscience. The authors thank Eric Kampmann for helpful discussions and proof-reading of the manuscript.

REFERENCES


M. Y amamoto, P. McCa

S. D. P . Quinn and U. De Boni, “Enhanced neuronal regen-

M. Clagett-Dame, E. M. McNeill, and P . D. Muley, “Role of

M. Maden, G. Keen, and G. E. Jones, “Retinoic acid as a


J. Xu, J. A. Chavis, M. K. Racke, and P. D. Drew, “Peroxisome


M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Perox-

M. Heneka, M. Sastre, L. Dumitrescu-Ozimek, et al.,

Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV7171 transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.

R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos,


M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Perox-

M. Clagett-Dame, E. M. McNeill, and P . D. Muley, “Role of

M. Maden, G. Keen, and G. E. Jones, “Retinoic acid as a


J. Xu, J. A. Chavis, M. K. Racke, and P. D. Drew, “Peroxisome


M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Perox-

M. Heneka, M. Sastre, L. Dumitrescu-Ozimek, et al.,

Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV7171 transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.

R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos,


M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Perox-

M. Heneka, M. Sastre, L. Dumitrescu-Ozimek, et al.,

Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV7171 transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.

R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos,


M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Perox-

M. Heneka, M. Sastre, L. Dumitrescu-Ozimek, et al.,

Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV7171 transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.

R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos,


M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Perox-

M. Heneka, M. Sastre, L. Dumitrescu-Ozimek, et al.,

Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV7171 transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.

R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos,
Submit your manuscripts at http://www.hindawi.com